A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals - Wikidata - awgldk - TriplyDB

A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals

A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals

http://www.wikidata.org/entity/Q34009093

about

How to Define the Latent Reservoir: Tools of the Trade Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction.Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.The HIV treatment cascade in acutely infected people: informing global guidelines.A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.Drug combination therapy increases successful drug repositioning.Update on antiretroviral treatment during primary HIV infection.Towards an HIV-1 cure: measuring the latent reservoir.Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.Single-molecule techniques to quantify and genetically characterise persistent HIV.Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.

P2860

Q26766705-C911D87F-24D6-45B0-8ED6-DAE37D331489 Q26801286-4E17C7F5-6446-4683-A703-54C78359ABCC Q26822422-C9F5D361-AABC-439F-A286-2089FE4A9A26 Q27014077-6B969EA9-A8C2-464F-847D-DDAF126AEAEF Q30690955-98530335-B638-44B2-8F44-01D29012E3BB Q33725916-23294265-7C47-4154-8A65-FE170C30DFFB Q33798207-B8D8F740-18CA-456B-B3F9-252B78213E03 Q35595846-F1C10D01-AE27-4457-AC08-2147693EA173 Q35629509-44F5A2B5-FB02-451B-AA09-842D35333F28 Q36210055-F60731B9-75DC-4136-9621-4921F0E60B98 Q36509593-F8EA9276-C770-44AD-9598-22D3579699CA Q36539990-2DFE006B-3BFD-4870-877F-0DB28EA855D6 Q36554974-8AA250AD-8695-4C32-B02C-41379F1ED5BB Q37004251-77EC9286-E480-4B0C-9A6B-312C64D86548 Q38209874-3198516C-3B13-4B0C-9745-A900678722ED Q38369541-0344DCB6-65E0-4746-AD50-4AD11974888E Q38686953-D1F58B44-5261-479C-AAE3-2A8A6203FF36 Q38749963-15E9FBDF-E109-4F20-BF7F-844E29A096C2 Q40072965-7A27D565-5924-4057-B801-55DB30994158 Q47556373-1E09E2DB-CCD7-412D-B81F-A43AC7644494 Q54211966-1D942901-D2D3-43A7-B675-15EA94B88736

P2860

A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals

http://www.wikidata.org/entity/Q34009093

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A randomized open-label study ...... wly HIV-1-infected individuals

@ast

A randomized open-label study ...... wly HIV-1-infected individuals

@en

A randomized open-label study ...... wly HIV-1-infected individuals

@nl

type

label

A randomized open-label study ...... wly HIV-1-infected individuals

@ast

A randomized open-label study ...... wly HIV-1-infected individuals

@en

A randomized open-label study ...... wly HIV-1-infected individuals

@nl

prefLabel

A randomized open-label study ...... wly HIV-1-infected individuals

@ast

A randomized open-label study ...... wly HIV-1-infected individuals

@en

A randomized open-label study ...... wly HIV-1-infected individuals

@nl

P1433

Q34009093-846C26CF-1E95-4968-BA7A-55788862C640

P1476

Q34009093-769BB674-AC3E-42D5-BF7D-E07607B2A1D0

P2093

Q34009093-5CA2FD84-A852-4596-8BB5-818AC8F83B24

Q34009093-B527EC31-72AF-4FA1-B746-1DB30B23D0FE

Q34009093-B6CDE2F0-DD39-41E7-83FD-C6B512E7B85B

Q34009093-B8A5FB8E-B64F-4F6F-A6F2-1ECB23EF7A5B

Q34009093-B9B96206-7E32-48B0-8B6D-7D010A7F2FCC

Q34009093-C554BEFC-2A50-4EC6-95B3-D1AD8C964995

Q34009093-C6B531BC-E5C9-4E27-9E1A-945A6075E253

Q34009093-E6CA91F1-01C9-43BB-82FC-00AFF93AC8AB

Q34009093-FA422050-FC1A-4835-A8CA-B4D957B18178

P2860

Q34009093-133A6F99-5044-454E-BBFB-14451B87FF82

Q34009093-2EB6E58D-72FE-4907-BD12-435A17099EDA

Q34009093-346A17FD-66E4-447B-B6FA-BC469B41FDFE

Q34009093-3D7AF8B8-9274-4BC5-B467-84D35F5F4122

Q34009093-3D800A14-0C97-48EE-A22B-34B7F39E7D1D

Q34009093-3F22771E-3A80-49C3-B57D-770EFFB7BA43

Q34009093-495FE622-8A14-4FC4-8A46-241D9C9C50C7

Q34009093-4BFF07DA-CC50-4B7D-9783-D7F14F7EB243

Q34009093-508A55AA-BCAF-47F7-8B53-53754BC40EA5

Q34009093-5767A32F-3B51-44FD-932B-BD3300CE7924

P304

Q34009093-B3401154-1FBC-4148-9555-0EBC19733ADF

P31

Q34009093-B5D47FA1-2AD4-45CC-8471-3127C3E49FEB

P356

Q34009093-33E419B7-591C-4377-A985-3034A4F59BA4

P407

Q34009093-BAC03A51-FA39-4341-B9CE-16383A175599

P433

Q34009093-DCEBE75E-A5CD-4E37-97F4-1C93686763B2

P478

Q34009093-5F598C83-6576-4935-B19A-5C981A30022D

P50

Q34009093-47A6B762-094F-46A3-8AEB-B21ACD1C5EFB

P577

Q34009093-68C29131-1C7C-4AC9-9511-7CF114DE84B9

P698

Q34009093-0B73F849-A214-453B-B51D-BD2AA5E4A6FF

P921

Q34009093-78F92CC0-0A86-47C2-8474-9A562837B278

P932

Q34009093-AB2C13BC-9C69-4051-B56B-9D84FB80BDAE

P356

QAI.0000000000000111

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

A randomized open-label study ...... wly HIV-1-infected individuals

@en

P2093

Donald Garmon

http://www.w3.org/2001/XMLSchema#string

Hiroshi Mohri

http://www.w3.org/2001/XMLSchema#string

Kristina Rodriguez

http://www.w3.org/2001/XMLSchema#string

Martin Markowitz

http://www.w3.org/2001/XMLSchema#string

Melissa La Mar

http://www.w3.org/2001/XMLSchema#string

Nicole Prada

http://www.w3.org/2001/XMLSchema#string

Sarah Palmer

http://www.w3.org/2001/XMLSchema#string

Teresa H Evering

http://www.w3.org/2001/XMLSchema#string

Vincent Sahi

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing chemokine co-receptor usage in HIV

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

P304

140-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000111

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24457632

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4123437

http://www.w3.org/2001/XMLSchema#string